Enzalutamide for patients with metastatic castration-resistant prostate cancer

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 871-876

  Ramadan, Wijdan H ^a   Kabbara, Wissam K ^a   Al Basiouni Al Masri, Hiba S ^b  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b BEIRUT ARAB UNIVERSITY   (Lebanon)

Author keywords

Castration resistant prostate cancer; Enzalutamide

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; BICALUTAMIDE; BOSENTAN; CARBAMAZEPINE; CREATININE; DNA; DOCETAXEL; EFAVIRENZ; ENZALUTAMIDE; ETRAVIRINE; GEMFIBROZIL; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; MIDAZOLAM; MODAFINIL; NAFCILLIN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISONE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; WARFARIN;

AMNESIA; APOPTOSIS; ARTHRALGIA; ASTHENIA; BACKACHE; BRONCHITIS; CASTRATION RESISTANT PROSTATE CANCER; CHILD PUGH SCORE; COGNITIVE DEFECT; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DNA BINDING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HOT FLUSH; HUMAN; LARYNGITIS; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MENTAL DISEASE; METASTASIS; OVERALL SURVIVAL; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; RHINOPHARYNGITIS; SEIZURE; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION;

EID: 84929463173     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S77297     Document Type: Review

References (22)

1. Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev. 2012;39:275–289.
2. American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. http://www.cancer.gov/cancertopics/types/commoncancers. Accessed March 15, 2015.
3. Scher HJ, Sawyers CL. Biology of progressive castration resistant prostate cancer: directed therapies targeting the androgen–receptor signaling axis. J Clin Oncol. 2005;23:8253–8261.
4. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res. 2011;17:1649–1657.
5. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–39.
6. US Food and Drug Administration. FDA Approves New Treatment for a Type of Late Stage Prostate Cancer; 2014. Available from: http://www.medscape.com/viewarticle/831548. Accessed January 5, 2015.
7. Xtandi. FDA Label for Enzalutamide – August 2012; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf. Accessed November 10, 2014.
8. Scher HI, Beer TM, Higano CS, et al; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–1446.
9. Tran C, Ouk S, Clegg NJ, et al. Development of a second generation antiandrogen for the treatment of advanced prostate cancer. Science. 2009;324:787–790.
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy (the AFFIRM trial). N Eng J Med. 2012;367(13):1187–1197.
11. Vogelzang NJ. Enzalutamide – a major advance in the treatment of metastatic prostate cancer. N Eng J Med. 2012;367(13):1256–1257.
12. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (the PREVAIL trial). N Engl J Med. 2014;371:424–433.
13. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2012;30(suppl):abstrLBA4518.
14. Clinical trials. A Study of MDV3100 Versus Bicalutamide in Castrate Men with Metastatic Prostate Cancer (TERRAIN); 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01288911?term=MDV3100&rank=13. Accessed March 15, 2015.
15. Pollack A. New Drug for Prostate Cancer Gets FDA Nod. New York: The New York Times; 2012.
16. Maverick NY. Abiraterone now Approved as Zytiga by the FDA for Castrate Resistant Prostate Cancer: Pharma Strategy Blog; 2011. Available from: http://pharmastrategyblog.com/2011/04/abiraterone-now-approved-as-zytiga-by-the-fda-in-castrate-resistant-prostate-cancer.html/. Accessed November 10, 2014.
17. Fizazi K, Scher HI, Molina A, et al. Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel. Eur J Cancer. 2011;47:S483–S484. [abstract 7000].
18. Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplerenone and prednisolone with wild type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012;72:2176–2182.
19. Holzbeierlein J, Lal P, Latulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen responsive genes and mechanism of therapy resistance. Am J Pathol. 2004;164:217–227.
20. Donkena KV, Yuan H, Young CY. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets. 2010;10:402–410.
21. Choudhury AD, Kantoff PW. New agents in metastatic prostate cancer. J Natl Compr Canc Netw. 2012;10:1403–1409.
22. American Association for Cancer Research. Enzalutamide shows efficacy in advanced prostate cancer. Cancer Discovery. 2012;2:OF5.